Background: There has been tremendous growth in research in pediatric multiple sclerosis (MS)
and immune mediated central nervous system demyelinating disorders since …

Background The three interferon beta preparations approved for treatment of relapsing-remitting
multiple sclerosis (MS) differ in dose and frequency of administration. Interferon beta-1a …

The onset of multiple sclerosis (MS) in childhood poses diagnostic and therapeutic challenges,
particularly if the symptoms of the first demyelinating event resemble acute disseminated …

Objectives: To evaluate the clinical characteristics, course and prognosis of Devic’s neuromyelitis
optica (DNO), to evaluate the prognostic role of demographic and clinical features, to …

Background Treatment of patients younger than 18 years of age with multiple sclerosis has
not been adequately examined in randomized trials. We compared fingolimod with interferon …

Background: There is limited and inconsistent information on the clinical determinants of
cognitive impairment (CI) in multiple sclerosis (MS). Objective: The aim of this study was to …

Background Movement-associated cortical reorganisation is known to occur in multiple sclerosis
(MS). We aimed to define the development of such cortical reorganisation by comparing …

OBJECTIVES Health related quality of life (HRQOL) inventories are multi-dimensional measures
of patient-centred health status developed for clinical research. The MS quality of life 54 …

The clinical features, diagnostic challenges, neuroimaging appearance, therapeutic options,
and pathobiological research progress in childhood—and adolescent—onset multiple …

Importance Cognitive impairment is a common and disabling feature of multiple sclerosis (MS),
but a precise characterization of cognitive phenotypes in patients with MS is lacking. …